<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316859</url>
  </required_header>
  <id_info>
    <org_study_id>17-020</org_study_id>
    <nct_id>NCT03316859</nct_id>
  </id_info>
  <brief_title>Naloxegol and Opioid-induced Constipation</brief_title>
  <official_title>A Prospective Randomized, Double-Blind Study to Evaluate the Addition of Naloxegol to the Pre-Op Regimen of the Cardiac Surgery Patient and Its Effect on Opioid-Induced Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angela Fellner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled trial to examine the effectiveness of
      adding one 25mg dose of naloxegol to the cardiac surgery pre-operative regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled trial to examine the effectiveness of
      adding one 25mg dose of naloxegol to the cardiac surgery pre-op regimen. There will be 140
      subjects per study group. The patient and treating physician/nurse will be blinded as to
      which group the subject is assigned. On the day of surgery, subjects in both groups will
      complete a questionnaire to assess compliance with prescribed pre-operative regimen. Subjects
      in both groups will receive post-operative bowel regimen in the cardiovascular intensive care
      unit (CVICU) according to current standard of care, including procedures for rescue
      medications for constipation prevention and induction of a bowel movement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">October 2, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to substantial bowel movement</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>Time to bowel movement of Type 2 or higher on the Bristol stool chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to substantial bowel movement</measure>
    <time_frame>Post-operative day 2</time_frame>
    <description>Time to bowel movement of Type 2 or higher on the Bristol stool chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to substantial bowel movement</measure>
    <time_frame>Post-operative day 3</time_frame>
    <description>Time to bowel movement of Type 2 or higher on the Bristol stool chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to substantial bowel movement</measure>
    <time_frame>Post-operative day 4</time_frame>
    <description>Time to bowel movement of Type 2 or higher on the Bristol stool chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to substantial bowel movement</measure>
    <time_frame>Post-operative day 5</time_frame>
    <description>Time to bowel movement of Type 2 or higher on the Bristol stool chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue medications</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>Amount of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medications</measure>
    <time_frame>Post-operative day 2</time_frame>
    <description>Amount of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medications</measure>
    <time_frame>Post-operative day 3</time_frame>
    <description>Amount of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medications</measure>
    <time_frame>Post-operative day 4</time_frame>
    <description>Amount of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medications</measure>
    <time_frame>Post-operative day 5</time_frame>
    <description>Amount of rescue medications</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of stay</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>CVICU length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay</measure>
    <time_frame>Post-operative day 2</time_frame>
    <description>CVICU length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay</measure>
    <time_frame>Post-operative day 3</time_frame>
    <description>CVICU length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay</measure>
    <time_frame>Post-operative day 4</time_frame>
    <description>CVICU length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay</measure>
    <time_frame>Post-operative day 5</time_frame>
    <description>CVICU length of stay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Constipation</condition>
  <condition>Constipation Drug Induced</condition>
  <arm_group>
    <arm_group_label>Naloxegol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>naloxegol 25 mg pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxegol 25 MG</intervention_name>
    <description>Naloxegol 25 mg administered 1 hour pre-operatively</description>
    <arm_group_label>Naloxegol</arm_group_label>
    <other_name>Movantik</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Placebo pill administered 1 hour pre-operatively</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo elective cardiac surgery at Bethesda North TriHealth Hospital

          -  Admitted to Bethesda North TriHealth Hospital CVICU post-surgery

        Exclusion Criteria:

          -  Medically unstable

          -  Cognitive deficits that impair the patient's ability to understand the informed
             consent

          -  Language barriers

          -  Patient has a documented diagnosis of one of the following: Crohn's disease;
             Ulcerative Colitis; History of bowel surgery that will impact absorption of study drug
             (as deemed by physician); History of small bowel obstruction

          -  Chronic constipation requiring subject to take one of the following medications on a
             daily basis prior to time of consent: Linzess, Trulance, Amitza, Senna/Senokot,
             Colace, Dulcolax, Miralax, Metamucil

          -  Patients on following medications prior to time of consent: Diltiazem, Verapamil,
             Amiodarone, Ketoconazole, Clarithromycin/ erythromycin, Antivirals

          -  Conditions that present an increased risk of bowel perforation (as determined by the
             physician)

          -  Pre-existing diagnosis of opioid-induced constipation AND receiving naloxegol as a
             treatment by their physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott McCardle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bethesda North TriHealth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jocelyn LaMar, BS</last_name>
    <phone>513-865-5072</phone>
    <email>Jocelyn_LaMar@trihealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lori Reid, MSN RN</last_name>
    <phone>513-865-5211</phone>
    <email>Lori_Reid@trihealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bethesda North TriHealth Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyn LaMar, BS</last_name>
      <phone>513-865-5072</phone>
      <email>Jocelyn_LaMar@trihealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4.</citation>
    <PMID>24896818</PMID>
  </reference>
  <reference>
    <citation>DePriest AZ, Miller K. Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther. 2014 Jun;3(1):1-15. doi: 10.1007/s40122-014-0026-2. Epub 2014 May 6.</citation>
    <PMID>25135384</PMID>
  </reference>
  <reference>
    <citation>Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015 Jul;8(4):206-20. doi: 10.1177/1756283X15578608. Review.</citation>
    <PMID>26136838</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>TriHealth Inc.</investigator_affiliation>
    <investigator_full_name>Angela Fellner</investigator_full_name>
    <investigator_title>Clinical Research Specialist</investigator_title>
  </responsible_party>
  <keyword>opioid-induced constipation (OIC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

